Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Co.'s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. We show 36 historical shares outstanding datapoints in our QURE shares outstanding history coverage, used to compute QURE market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing QURE market cap history over the course of time is important for investors
interested in comparing QURE's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of QURE versus a peer is one thing; comparing
QURE market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like QURE can fluctuate over the course of history.
With this page we aim to empower investors researching QURE by allowing them to research the QURE market cap history. |
Free QURE Email Alerts:
Video: The Importance of Market Cap
